



PERSONAL INFORMATION

Name

BRACARDA SERGIO

Address

**MEDICAL AND TRANSLATIONAL ONCOLOGY UNIT, DEPARTMENT OF
ONCOLOGY, AZIENDA OSPEDALIERA SANTA MARIA, TERNI, VIALE
TRISTANO DI JOANNUCCIO 1; 05100 TERNI, ITALY**

C.F.

BRC SRG 55L11 G478 O

Telephone

Fax

E-mail

s.bracarda@aosp terni.it ; sergiobracarda@gmail.com

Nationality

Italian

Date of birth

July 11, 1955

WORK EXPERIENCE

From April 2021

Director of the Department of Oncology, Azienda Ospedaliera Santa Maria, Terni; Italy

2018 to date

Director of the Medical and Translational Oncology Unit (Italian: S.C. di Oncologia Medica e Traslazionale), Department of Oncology, Azienda Ospedaliera Santa Maria, Terni; Italy

2014 - 2018

Director of the Department of Oncology, USL-8 Arezzo (and, from 2016, of the new larger USL Toscana Sud-Est), Istituto Toscano Tumori (ITT), Italy

2009 - 2018

Director of the Medical Oncology Unit, Department of Oncology, Ospedale San Donato, USL-8 Arezzo, Istituto Toscano Tumori (ITT), Italy

1999 - 2009

Senior Oncologist and Section Chief of Oncology-Urology in the Medical Oncology Division, Policlinico Hospital, Perugia;

1996 -1999

Senior Registrar/Consultant Oncologist in the Department of Urology, Perugia University;

1993 -1995

Junior Registrar/Consultant Oncologist in the Department of Urology, Perugia University; Postgraduate School in Urology

1986 -1992

Resident in the Department of Medical Oncology of Perugia

• Name and address of employer

*Az. Ospedaliera Santa Maria, Viale Tristano di Joannuccio 1, Terni;
Italy*

Type of business or sector	Medical Oncology
Occupation or position held	Director: Medical Oncology
Main activities and responsibilities	Main fields of research in treatment of: Advanced Prostate Cancer Advanced Renal Cell Carcinoma Locally advanced and metastatic Urothelial Cancer CNS tumours, mainly Glioblastoma Translational research on Immunotherapy, targeted agents and other Innovative anticancer treatments and combination approaches Treatment personalization approaches
From October 2022	President of the Italian Society for Uro-Oncology (SIUrO)

EDUCATION AND TRAINING

1999	University of Perugia, School of Medicine, Specialization in Urology cum laude
1991	Sacred Heart Catholic University of Rome, School of Medicine, Specialist in Medical Oncology cum laude
1986	University of Perugia, School of Medicine, Medical Degree cum laude
• Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded • Level in national classification (if appropriate)	University of Perugia Sacred Heart Catholic University of Rome Medical Degree in Medicine; two Specializations: Medical Oncology and Urology National Scientific Qualification as Associate Professor in the Higher education system in the call 2018/2020 (National Classification 06/D3) National Scientific Qualification as Full Professor in the Higher education system in the call 2018/2020 (National Classification 06/D3)

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

• Reading skills	ENGLISH EXCELLENT
------------------	----------------------

- Writing skills
- Verbal skills

TECHNICAL SKILLS AND COMPETENCES

**With computers, specific
kinds of equipment,
machinery, etc.**

ADDITIONAL INFORMATION

EXCELLENT
EXCELLENT

NORMALLY USING PERSONAL COMPUTER PROGRAMS, ESPECIALLY MICROSOFT OFFICE (WORD, EXCEL POWER POINT, OUTLOOK), INTERNET AND MAILING UTILITIES

At the moment **230** publications (plus more than 500 abstracts) in peer-reviewed journals. One text on "Informed consent in Oncology and Hemato-Oncology", some chapters about issues of genitourinary oncology in published textbooks.

Active Member of:


- American Society of Clinical Oncology (**ASCO**)
- European Society for Medical Oncology (**ESMO**)
- European Association of Urology (**EAU**)
- Italian Society of Medical Oncology (**AIOM**)
- Italian Society for Urology-Oncology (**SIUrO**)

H Index (SCOPUS): 51

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della L. 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996. Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali, del Decreto Legislativo 101/2018 e del GDPR 679/2016.

ANNEXES

Terni, September 30, 2024



Sergio Bracarda MD,

Director: Department of Oncology and Oncology Unit,

Azienda Ospedaliera Santa Maria di Terni, Viale Tristano di Joannuccio 1; 05100 Terni, Italy

Bibliography (n° 230 Articles at September 30, 2024):

230. Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, **Bracarda S**, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. *Ann Oncol.* 2024 Sep 9:S0923-7534(24)03996-6.

229. Ruiz-Vico M, Wetterskog D, Orlando F, Thakali S, Wingate A, Jayaram A, Cremaschi P, Vainauskas O, Brighi N, Castellano-Gauna D, Åström L, Matveev VB, **Bracarda S**, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Gupta S, Wenstrup R, Boysen G, Martins K, Iwata K, Chowdhury S, Gourgioti G, Serikoff A, Gonzalez-Billalabeitia E, Merseburger AS, Demichelis F, Attard G. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. *Eur Urol Oncol.* 2024 Sep 10:S2588-9311(24)00188-3.

228. Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. LITESPARK-005 Investigators. *N Engl J Med.* 2024 Aug 22;391(8):710-721. (**Name in the Appendix List**)

227. Guida A, Mosillo C, Mammone G, Caserta C, Sirgiovanni G, Conteduca V, **Bracarda S**. The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer. *Cancer Treat Rev.* 2024 Jul;128:102766.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winkquist E, Corneli J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators.

N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695.

PMID: 38631003 Clinical Trial.

226. Brunelli M, Gobbo S, Malpeli G, Sirgiovanni G, Caserta C, Munari E, Francesconi S, Calì A, Martignoni G, Cimadamore A, Vecchia A, Antonelli A, Tucci M, Pierconti F, Hattab IM, Eccher A, Ascani S, Milella M, Buffoni L, Cheng L, **Bracarda S**. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. *Pathologica.* 2024 Feb;116(1):55-61.

224. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. *N Engl J Med.* 2024 Mar 7;390(10):875-888. (**Name in the Appendix List**)

223. Bauckneht M, Ciccarese C, Laudicella R, Mosillo C, D'Amico F, Anghelone A, Strusi A, Beccia V, **Bracarda S**, Fornarini G, Tortora G, Iacovelli R. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives. *Cancer Treat Rev.* 2024 Mar;124:102698.

222. Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, **Bracarda S**, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R,

Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. *J Clin Oncol*. 2024 Apr 20;42(12):1403-1414.

221. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfield C, Nagasaka M, Filip E, Yang N, Velcheti V, Lu S, Kao S, Doooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2024 Jan 11;390(2):118-131. **(Name in the Appendix List)**

220. Canovai M, Evangelista M, Mercatanti A, D'Aurizio R, Pitto L, Marrocolo F, Casieri V, Pellegrini M, Lionetti V, **Bracarda S**, Rizzo M. Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells. *Cell Death Discov*. 2023 Dec 8;9(1):445.

219. Cimadamore A, Rescigno P, Conteduca V, Calò A, Allegritti M, Calò V, Montagnani I, Lucianò R, Patruno M, **Bracarda S**; Italian Society for Uro-Oncology (SIUrO). SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP). *Virchows Arch*. 2023 Nov;483(5):579-589.

218 Tarantini L, Di Girolamo S, Masini C, Cioffi G, Foglietta J, **Bracarda S**, Pinto C, Navazio A. [Hormone therapy, cardio-metabolic profile, and cardiotoxicity. Still a dark side of cardio-oncology - Part 2: Prostate cancer]. *G Ital Cardiol (Rome)*. 2023 Oct;24(10):781-791.

217. **Bracarda S**, Iacovelli R, Baldazzi V, Zucali PA, Gernone A, Conti GN, Pappagallo G, Brunelli M, Bruzzi P, Fiorini E, Magenta L, Diomede F, Mereta F, D'Aria I, Magliano D, Liberatori M, Cantù D, Croce D, Eandi S, Colombo GL, Ferrante F, Salè EO, Marinozzi A, Lenzi D, Remiddi F, Remiddi S. U-CHANGE Project: a multidimensional consensus on how clinicians, patients and caregivers may approach together the new urothelial cancer scenario. *Front Oncol*. 2023 Jul 28;13:1186103.

216. Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanavaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Kúronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bissoni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, **Bracarda S**, Porta C. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? *Eur Urol Oncol*. 2024 Feb;7(1):102-111.

215. Ascierto PA, Avallone A, Bifulco C, **Bracarda S**, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, Kirchhoff T, Klebanoff CA, Lesinski GB, Monette A, Neyns B, Odunsi K, Paulos CM, Powell DJ Jr, Rezvani K, Segal BH, Singh N, Sullivan RJ, Fox BA, Puzanov I. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). *J Transl Med*. 2023 Jul 20;21(1):488.

214. Internò V, Massari F, Rudà R, Maiorano BA, Caffo O, Procopio G, **Bracarda S**, Atzori F, Passarelli A, Bersanelli M, Stellato M, Fornarini G, Galli L, Ortega C, Zanardi E, Incorvaia L, Facchini G, Giron Berrios JR, Ricotta R, Santoni M, Funaioli C, Trerotoli P, Porta C, Rizzo M. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. *ESMO Open*. 2023 Aug;8(4):101598.

213. O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, **Bracarda S**, Borchellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE.

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117.

212. Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, Pérez-Gracia JL, Llácer Pérez C, Shin SJ, Fang B, Barve M, Maruzzo M, **Bracarda S**, Kim M, Kerloeguen Y, Gallo JD, Maund SL, Harris A, Huang KC, Poon V, Sutaria DS, Gurney H. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2023 Sep 1;29(17):3292-3300.

211. Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023 May 11;388(19):1767-1778. (*Name in the Appendix List*)

210. Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, **Bracarda S**, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023 May 1;CCR-22-3116.

209. Chi KN, Rathkopf D, Smith MR, Efsthathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Mar 23;JCO2201649. (*Name in the Appendix List*)

208. Lapini A, Caffo O, Conti GN, Pappagallo G, Del Re M, D'Angelillo RM, Capoluongo ED, Castiglione F, Brunelli M, Iacovelli R, De Giorgi U, **Bracarda S**. Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project. Crit Rev Oncol Hematol. 2023 Apr;184:103959. Epub 2023 Mar 13. PMID: 36921782 Review.

207. Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Apthorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D'Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, Patriarca A, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D'Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Lancet Oncol. 2023 Apr;24(4):335-346. (*Name in the Appendix List*)

206. Berruti A, **Bracarda S**, Caffo O, Cortesi E, D'Angelillo R, Del Re M, Facchini G, Pappagallo G, Procopio G, Sabbatini R, Santini D. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat Rev. 2023 Apr;115:102525..

205. Matsubara N, de Bono J, Sweeney C, Chi KN, Olmos D, Sandhu S, Massard C, Garcia J, Chen G, Harris A, Schenkel F, Sane R, Hinton H, Bracarda S, Sternberg CN. Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Jan 7:S1558-7673. (*Name in the Appendix List*)

204. Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli L, Rizzo M, De Giorgi U, Antonuzzo L, **Bracarda S**, Cartenì G, Atzori F, Tamberi S, Procopio G, Fratino L, Lo Re G, Santoni M, Baldessari C, Astone A, Calabrò F, Brunelli M, Porta C, Rescigno P, Basso U, Fornarini G. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. *ESMO Open*. 2022 Dec;7(6):100634.
203. Arcidiacono F, Anselmo P, Casale M, Zannori C, Ragusa M, Manciola F, Marchetti G, Loreti F, Italiani M, **Bracarda S**, Maranzano E, Trippa F. STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RADio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial. *Int J Radiat Oncol Biol Phys*. 2022 Oct 24:S0360-3016(22)03459-9.
202. Merseburger AS, Attard G, Åström L, Matveev VB, **Bracarda S**, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. *Lancet Oncol*. 2022 Nov;23(11):1398-1408.
201. Mosillo C, Calandrella ML, Caserta C, Macrini S, Guida A, Sirgiovanni G, **Bracarda S**. Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data? *Cancers (Basel)*. 2022 Aug 29;14(17):4189.
200. Del Re M, Crucitta S, Paolieri F, Cucchiara F, Verzoni E, Bloise F, Ciampi R, Mercinelli C, Capuano A, Sportiello L, Martinetti A, Procopio G, Galli L, Porta C, **Bracarda S**, Danesi R. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. *J Transl Med*. 2022 Aug 16;20(1):371.
199. Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta MG, Caserta C, Bimbatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, **Bracarda S**, De Giorgi U, Basso U, Tortora G, Procopio G. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. *Clin Genitourin Cancer*. 2022 Oct;20(5):498.e1-498.e9.
198. Guida A, Tassi V, Facchinetti F, Marchetti G, Caprera C, Ragusa M, Tiseo M, Bracarda S, **Bracarda S**. Ad hoc afatinib in an elderly lung cancer patient with EGFR exon 19 deletion L747-A750>P. *Adv Respir Med*. 2022;90(3):234-235.
197. Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, Sureda A, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Lee AJX, Sng CCT, Liñan R, Rossi S, Carmona-García MC, Sharkey R, Eremiev S, Rizzo G, Bain HD, Yu T, Cruz CA, Perachino M, Saoudi-Gonzalez N, Fort-Culillas R, Doonga K, Fox L, Roldán E, Zoratto F, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Shawe-Taylor M, Fusco V, Martinez-Vila C, Berardi R, Filetti M, Mazzoni F, Santoro A, Delfanti S, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tabernero J, Gennari A, Cortellini A; OnCovid study group. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. *Eur J Cancer*. 2022 Aug;171:64-74. (**Name in the Appendix List**)
196. Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, **Bracarda S**, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. *J Transl Med*. 2022 Jun 7;20(1):257.
195. Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom-Davis T, Handford J, Sita-Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona-García MC, Sharkey R, García-Illescas D, Rizzo G, Perachino M, Saoudi-Gonzalez N, Doonga K, Fox L, Roldán E, Gaidano G, Ruiz-Camps I, Bruna R,

Patriarca A, Martinez-Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A; OnCovid study group. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. *Lancet Oncol.* 2022 Jul;23(7):865-875. (**Name in the Appendix List**)

194. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, **Bracarda S**, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calì A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. *J Pers Med.* 2022 Apr 30;12(5):727.

193. Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open.* 2022 May 18;7(3):100459. (**Name in the Appendix List**)

192. Basso U, Paolieri F, Rizzo M, De Giorgi U, **Bracarda S**, Antonuzzo L, Atzori F, Carteni G, Procopio G, Fratino L, D'Arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. *Cancers (Basel).* 2022 May 4;14(9):2293.

191. Macrini S, Francesconi S, Caprera C, Lancia D, Corsi M, Gunnellini M, Rocchi A, Pireddu A, Marziani F, Mosillo C, Calandrella ML, Caserta C, Giannarelli D, Guida A, Ascani S, **Bracarda S**. Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study. *Cancers (Basel).* 2022 Mar 17;14(6):1542.

190. Santoni M, Massari F, **Bracarda S**, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. *Eur Urol Focus.* 2022 Feb 19:S2405-4569(22)00049-9.

189. Calandrella ML, Francesconi S, Caprera C, Mosillo C, Caserta C, Giannarelli D, Corsi M, Macrini S, Guida A, Ascani S, **Bracarda S**. Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study. *BMC Cancer.* 2022 Feb 14;22(1):168

188. Desiderio J, Sagnotta A, Terrenato I, Garofoli E, Mosillo C, Trastulli S, Arteritano F, Tozzi F, D'Andrea V, Fong Y, Woo Y, **Bracarda S**, Parisi A. Long-term survival of patients with stage II and III gastric cancer who underwent gastrectomy with inadequate nodal assessment. *World J Gastrointest Surg.* 2021 Nov 27;13(11):1463-1483.

187. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B,

Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. *Lancet Oncol.* 2021 Dec;22(12):1669-1680. (**Name in the Appendix List**)

186. Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, **Bracarda S**, Procopio G, Porta C. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. *Ther Adv Urol.* 2021 Oct 22;13:17562872211054302.

185. Trastulli S, Desiderio J, Lin JX, Reim D, Zheng CH, Borghi F, Cianchi F, Norero E, Nguyen NT, Qi F, Coratti A, Cesari M, Bazzocchi F, Alimoglu O, Brower ST, Pernazza G, D'Imporzano S, Azagra JS, Zhou YB, Cao SG, Garofoli E, Mosillo C, Guerra F, Liu T, Arcuri G, González P, Staderini F, Marano A, Terrenato I, D'Andrea V, **Bracarda S**, Huang CM, Parisi A. Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database. *Cancers (Basel).* 2021 Sep 8;13(18):4526.

184. Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, **Bracarda S**, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. *Cancer Immunol Immunother.* 2022 Apr;71(4):865-874.

183. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N Engl J Med.* 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. (**Name in the Appendix List**)

182. Sweeney C, **Bracarda S**, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, Atduev V, Buchschacher GL Jr, Gafanov R, Corrales L, Borre M, Stroyakovskiy D, Alves GV, Bournakis E, Puente J, Harle-Yge ML, Gallo J, Chen G, Hanover J, Wongchenko MJ, Garcia J, de Bono JS. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. *Lancet.* 2021 Jul 10;398(10295):131-142

181. Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Pala L, Queirolo P, **Bracarda S**, Macrini S, Gori S, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, Ascierto PA, Pinato DJ, Ficorella C, Porzio G, Cortellini A. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. *J Transl Med.* 2021 Jun 24;19(1):270.

180. Tassi V, Mosillo C, Mutignani M, Ciocchi R, Ragusa M, **Bracarda S**, Passalacqua G, Marinozzi G, Allegritti M. Biliothoracic Fistula after Microwave Ablation of Liver Metastasis : Literature Review. *Emerg Med Int.* 2021 May 11;2021:9913076.

179. Buti S, Bersanelli M, Perrone F, **Bracarda S**, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bissoni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. *Eur J Cancer*. 2021 Jun;150:224-231.
178. Desiderio J, Sagnotta A, Terrenato I, Annibale B, Trastulli S, Tozzi F, D'Andrea V, **Bracarda S**, Garofoli E, Fong Y, Woo Y, Parisi A. Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. *Sci Rep*. 2021 Mar 30;11(1):7150.
177. Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma 176 A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, **Bracarda S**, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G. Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *Eur J Cancer*. 2021 Mar 12;148:24-35.
176. Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, **Bracarda S**, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. *Eur Urol*. 2021 Mar 4:S0302-2838(21)00003-8.
175. Choueiri TK, Powles T, Burotto M, Escudier B, Boursicot MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierczyk J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2021 Mar 4;384(9):829-841. (**Name in the Appendix List**)
174. Santoni M, Massari F, **Bracarda S**, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Carteni G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? *Diagnostics (Basel)*. 2021 Jan 18;11(1):138.
173. Palumbo C, Bruni A, Antonelli A, Artibani W, Bassi PF, Bertoni F, Borghetti P, **Bracarda S**, Cicchetti A, Corvò R, Gacci M, Ingrosso G, Magrini SM, Maruzzo M, Mirone V, Montironi R, Muto G, Noale M, Porreca A, Russi E, Triggiani L, Tubaro A, Valdagni R, Maggi S, Conti GN; Pros-IT CNR Study Group. Health-related quality of life 24-month after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. *Minerva Urol Nefrol*. 2021 Jan 13.
172. Santoni M, Piva F, Porta C, **Bracarda S**, Heng DY, Matrana MR, Grande E, Mollica V, Aurilio G, Rizzo M, Giulietti M, Montironi R, Massari F. Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. *Clin Genitourin Cancer*. 2020 Nov 10:S1558-7673(20)30250-0.
171. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Vecchia A, Guglielmini PF, Maruzzo M, Rossi E, Grossi F, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, Battelli N, Fornarini G, Mucciarini C, **Bracarda S**, Bonetti A,

Pezzuolo D, Longo L, Sartori D, Iannopollo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gernone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carrozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. *Ther Adv Med Oncol*. 2020 Nov 2;12:1758835920968463. eCollection 2020.

170. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, **Bracarda S**, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *Eur J Cancer*. 2021 Jan;142:18-28.

169. Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, **Bracarda S**, Briganti A, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, Crepaldi G; Pros-IT CNR Study Group. *Minerva Urol Nefrol*. 2020 Nov 17.

168. Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bissoni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petraghani N, Pala L, **Bracarda S**, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. *J Immunother Cancer*. 2020 Nov;8(2):e001361.

167. Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi SE, Procopio G, Verzoni E, **Bracarda S**, Sabbatini R, Baldessari C, Eccher A, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calì A, Alongi F, Munari E, Pappagallo G, Iacovelli R, Mosca A, Porta C, Martignoni G, Antonelli A. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *J Clin Pathol*. 2020 Nov 3; jclinpath-2020-207089.

166. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, **Bracarda S**, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. *Target Oncol*. 2020 Oct;15(5):691.

165. Gacci M, Artibani W, Bassi P, Bertoni F, **Bracarda S**, Briganti A, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Greco I, Maggi S, Magrini SM, Mirone V, Montironi R, Morgia G, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Russo G, Salonia A, Simonato A, Serni S, Tomasini D, Tubaro A, Zagonel V, Crepaldi G; MIRROR-SIU/LUNA Study Group and the Pros-IT CNR Study Group. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. *World J Urol*. 2020 Aug 1.

164. Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, **Bracarda S**, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giaquinta S, Balduzzi S, D'Amico R, Vitale G, Mighali P, Sabbatini R. Correlation Between Immune-related Adverse Event (irAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional

163 Iacovelli R, Ciccarese C, Bria E, **Bracarda S**, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020 Sep;136:195-203.

162. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, **Bracarda S**, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Target Oncol. 2020 Aug;15(4):495-501.

161. Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, **Bracarda S**, Bedke J, De Giorgi U, Porta C, Ravaud A, Parnis F, Grande E, Zhang W, Huseni M, Carroll S, Sufan R, Schiff C, Atkins MB. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. Eur Urol. 2020 Jul 9:S0302-2838(20)30450-4.

160. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzuttilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, **Bracarda S**, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer. 2020 Jul;134:19-28.

159 Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, **Bracarda S**, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piau-Louis E, Powles T. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020 Jul;126(1):73-82.

158. Santini D, Berruti A, Di Maio M, Procopio G, **Bracarda S**, Ibrahim T, Bertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open. 2020 Mar;5(2):e000652.

157. Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, **Bracarda S**, Stadler WM, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grulich C, Quach C, Carroll S, Ding B, Zhu QC, Piau-Louis E, Schiff C, Escudier B. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 Jun 1;26(11):2506-2514.

156. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, **Bracarda S**, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 Mar;128:17-26.

155. Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, **Bracarda**

S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fagnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. *Oncoimmunology*. 2020 Jan 7;9(1):1710389.

154 **Bracarda S**, Mosillo C, Trippa F, Urbano F, Maranzano E, Caserta C. No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases. *Ann Transl Med*. 2019 Nov;7(22):612.

153. Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, **Bracarda S**, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S; Pros-IT CNR study group. Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study). *Minerva Urol Nefrol*. 2020 Oct;72(5):595-604.

152. Santoni M, Heng DY, **Bracarda S**, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers (Basel)*. 2019 Dec 30;12(1):84.

151. Lapini A, Caffo O, Pappagallo G, Iacovelli R, D'Angelillo RM, Vavassori V, Ceccarelli R, **Bracarda S**, Jereczek-Fossa BA, Da Pozzo L, Conti GN. Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. *Cancers (Basel)*. 2019 Dec 1;11(12):1908.

150. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2020 Jan;21(1):105-120. **(Name in the Appendix List)**

149 De Nunzio C, Lombardo R, Tema G, Voglino O, Sica A, Baldassarri V, Nacchia A, Iacovelli R, **Bracarda S**, Tubaro A. Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. *Prostate Cancer Prostatic Dis*. 2020 Jun;23(2):199-206.

148. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, **Bracarda S**, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DY, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2019 Oct;20(10):1370-1385.

147. Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, **Bracarda S**. Toward a genome-based treatment landscape for renal cell carcinoma. *Crit Rev Oncol Hematol*. 2019 Oct;142:141-152.

146. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med*. 2019 Jul 25;381(4):338-348. **(Name in the Appendix List)**
145. Malik Z, Heidenreich A, **Bracarda S**, Ardavanis A, Parente P, Scholz HJ, Ozatilgan A, Ecstein-Fraisse E, Hitier S, Di Lorenzo G. Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. *Oncotarget*. 2019 Jun 25;10(41):4161-4168.
144. Vitale MG, **Bracarda S**, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori*. 2019 Jul;105(4_suppl):3-12.
143. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, **Bracarda S**, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piau-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet*. 2019 Jun 15;393(10189):2404-2415.
142. **Bracarda S**, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. *Clin Genitourin Cancer*. 2019 Jun;17(3):e689-e703.
141. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, **Bracarda S**, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. *Front Oncol*. 2019 Apr 5;9:228.
140. Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Loporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, **Bracarda S**, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer*. 2019 Mar 29;19(1):283.
139. Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, **Bracarda S**, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fagnoli MC, Ascierto PA, Ficarella C. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. *Oncologist*. 2019 Jun;24(6):e327-e337.
138. Antonelli A, Palumbo C, Noale M, Porreca A, Maggi S, Simeone C, Bassi P, Bertoni F, **Bracarda S**, Buglione M, Conti GN, Corvò R, Gacci M, Mirone V, Montironi R, Triggiani L, Tubaro A, Artibani W; Pros-IT CNR study group. Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study). *Urol Int*. 2019 Feb 7:1-11.

137. **Bracarda S**, Porta C, Sabbatini R, Rivoltini L. Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Crit Rev Oncol Hematol. 2019 Jul;139:149-157.
136. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, **Bracarda S**, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjunwala S, Piau-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Dec;24(12):1941.
135. de Bono JS, De Giorgi U, Nava Rodrigues D, Massard C, **Bracarda S**, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel P, Maslyar DJ, Jinga V. Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss. Clin Cancer Res. 2019 Feb 1;25(3):928-936.
134. **Bracarda S**, Guida A, Caserta C. "To Cut or Not to Cut", a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol. 2018 Oct;74(4):481-482.
133. Magnani T, **Bracarda S**, D'Angelillo RM, Artibani W, Barni S, Beretta G, Brausi M, Caffo O, Corvò R, Gallucci M, Gunelli R, Mirone V, Novara G, Pinto C, Russi E, Santoni R, Tomirotti M, Volpe A, Conti G, Valdagni R. Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. Tumori. 2018 Jul 1;300891618784789.
132. De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, **Bracarda S**, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. Italian Nivolumab Renal Cell Cancer Early Access Program Group. BJU Int. 2018 Jun 29.
131. Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, **Bracarda S**, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. Health Qual Life Outcomes. 2018 Jun 13;16(1):122.
130. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, **Bracarda S**, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjunwala S, Piau-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749-757.
129. **Bracarda S**, Galli L, Maruzzo M, Lo Re G, Buti S, Favaretto A, Di Costanzo F, Sacco C, Merlano M, Mucciarini C, Zafarana E, Romito S, Maestri A, Giorgio CG, Ionta MT, Turci D, De Giorgi U, Procopio G, Cortesi E, Giannarelli D, Porta C. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncol. 2018 Jun;14(14):1347-1354.
128. Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, **Bracarda S**, Santini D, Danesi R. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. Crit Rev Oncol Hematol. 2018 May;125:51-59.
127. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R,

Ravaud A, Grimm MO, **Bracarda S**, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. CheckMate 214 Investigators. *N Engl J Med*. 2018 Apr 5;378(14):1277-1290.

126. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. SPARTAN Investigators (**Name in the Appendix List**). *N Engl J Med*. 2018 Apr 12;378(15):1408-1418.

125. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Loughheed JC, **Bracarda S**, Choueiri TK. *J Clin Oncol*. 2018 Jan 8;JCO2017747352.

124. Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. Gacci M, Noale M, Artibani W, Bassi PF, Bertoni F, **Bracarda S**, Conti GN, Corvò R, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group. *Eur Urol Focus*. 2017 Nov 13. pii: S2405-4569(17)30246-8.

123. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators (**Name in the Appendix List**). *Lancet*. 2017 Nov 18;390(10109):2266-2277.

122. Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. Di Paolo A, **Bracarda S**, Arrigoni E, Danesi R. *Front Pharmacol*. 2017 Aug 7;8:523. doi: 10.3389/fphar.2017.00523. eCollection 2017. No abstract available.

121. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance. Bascetta L, Oliviero A, D'Aurizio R, Evangelista M, Mercatanti A, Pellegrini M, Marrocolo F, **Bracarda S**, Rizzo M. *Int J Mol Sci*. 2017 Jul 13;18(7).

120. Editorial Comment. **Bracarda S**, Duranti S, Roviello G. *J Urol*. 2017 Jun 19. pii: S0022-5347(17)74860-4.

119. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators (**Name in the Appendix List**). *N Engl J Med*. 2017 Jul 27;377(4):352-360

118. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, **Bracarda S**, Santini D, Danesi R. *Cancer Treat Rev*. 2017 Apr;55:71-82.

117. Pros-IT CNR: an Italian prostate cancer monitoring project. Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, **Bracarda S**, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group. *Aging Clin Exp Res*. 2017 Apr;29(2):165-172.

116. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D,

Grimm MO, **Bracarda S**, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. *Lancet Oncol*. 2017 Mar;18(3):312-322.

115. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Bracarda S, Negrier S, Casper J, Porta C, Schmidinger M, Larkin J, Gross Goupil M, Escudier B. *Expert Rev Anticancer Ther*. 2017 Mar;17(3):227-233.

114. IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, **Bracarda S**, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T. *Lancet Oncol*. 2016 Nov;17(11):1599-1611.

113. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Escudier B, Molinier V, **Bracarda S**, Maroto P, Szczylik C, Nathan P, Negrier S, Weiss C, Porta C, Grünwald V, Albiges L. *Eur J Cancer*. 2016 Dec;69:226-235.

112. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, Thompson JA, Figlin RA, Ravaud A, Basaran M, Porta C, **Bracarda S**, Brechenmacher T, Lin C, Voi M, Grünwald V, Motzer RJ. *Clin Genitourin Cancer*. 2016 Oct;14(5):406-414.

111. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Di Lorenzo G, **Bracarda S**, Gasparro D, Gernone A, Messina C, Zagonel V, Puglia L, Bosso D, Dondi D, Sonpavde G, Lucarelli G, De Placido S, Buonerba C. *Medicine (Baltimore)*. 2016 Jan;95(2):e2299.

110. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. **Bracarda S**, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. *Ann Oncol*. 2016 Feb;27(2):366.

109. Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. Massari F, Modena A, Ciccarese C, Pilotto S, Maines F, **Bracarda S**, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. *Crit Rev Oncol Hematol*. 2016 Feb;98:254-63.

108. More colors to the palette. Bracarda S. *Ann Oncol*. 2016 Feb;27(2):363.

107. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. *Future Oncol*. 2015 Nov;11(22):3083-90.

106. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators (**Name in the Appendix List**). *N Engl J Med*. 2015 Nov 5;373(19):1814-23.

105. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gaurer TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin

J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators (**Name in the Appendix List**). N Engl J Med. 2015 Nov 5;373(19):1803-13.

104. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. **Bracarda S**, Rottey S, Bahl A, Eichelberg C, Mellado B, Mangel L, Cattaneo A, Panneerselvam A, Grünwald V. Future Oncol. 2015;11(21):2893-903.

103. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Ann Oncol. 2015 Dec;26(12):2392-8.

102. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. **Bracarda S**, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Ann Oncol. 2015 Oct;26(10):2107-13. Erratum in: Ann Oncol. 2016 Feb;27(2):366.

101. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Gore ME, Szczylik C, Porta C, **Bracarda S**, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Br J Cancer. 2015 Jun 30;113(1):12-9.

100. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. **Bracarda S**, Altavilla A, Hamzaj A, Sisani M, Marrocolo F, Del Buono S, Danielli R. Semin Oncol. 2015 Jun;42(3):495-505.

99. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Powles T, **Bracarda S**, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N. Eur J Cancer. 2015 Jul;51(10):1293-302.

98. Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study. **Bracarda S**; RAINBOW Study Group. Ann Oncol. 2015 Jul;26(7):1512-3.

97. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, **Bracarda S**, Tonini G, Cascinu S, Santini D. J Exp Clin Cancer Res. 2015 Feb 5;34:10.

96. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators (**Name in the Appendix List**). Lancet Oncol. 2015 Feb;16(2):152-60.

95. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Sternberg CN, Calabrò F, **Bracarda S**, Carteni G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C. Oncology. 2015;88(5):273-80.

94. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, **Bracarda S**, Basso U, De Giorgi

U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. *Target Oncol*. 2015 Dec;10(4):517-22.

93. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, **Bracarda S**, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. *Ann Surg Oncol*. 2015;22(6):2094-100.

92. Steroids in prostate cancer: the jury is still out... and even more confused. Porta C, Bracarda S, Danesi R. *Eur Urol*. 2015 Apr;67(4):680-1.

91. Comparing comparators: a look at control arms in kidney cancer studies over the years. **Bracarda S**, Porta C, Sisani M, Marrocolo F, Paglino C, Hamzaj A, D Buono S, Sternberg CN. *Br J Cancer*. 2015 Jan 6;112(1):14-9.

90. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A. *Expert Rev Anticancer Ther*. 2014 Nov;14(11):1283-94.

89. Prostate changes related to therapy: with special reference to hormone therapy. Mazzucchelli R, Lopez-Beltran A, Galosi AB, Zizzi A, Scarpelli M, **Bracarda S**, Cheng L, Montironi R. *Future Oncol*. 2014 Aug;10(11):1873-86.

88. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, **Bracarda S**, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. *Crit Rev Oncol Hematol*. 2015 Jan;93(1):50-9.

87. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, **Bracarda S**, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. *J Urol*. 2015 Jan;193(1):41-7.

86. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. Santoni M, **Bracarda S**, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G, Cascinu S. *Biomed Res Int*. 2014;2014:768758.

85. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team. *Clin Lung Cancer*. 2014 Sep;15(5):338-45.e1.

84. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team. *J Cancer Res Clin Oncol*. 2014 Oct;140(10):1783-93.

83. Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators (**Name in the Appendix List**). *N Engl J Med*. 2014 Jul 31;371(5):424-33.

82. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK. Clin Genitourin Cancer. 2014 Aug;12(4):262-9.
81. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, **Bracarda S**, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Eur J Cancer. 2014 Jun;50(9):1617-27.
80. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, Schmidinger M. Expert Opin Drug Saf. 2014 Apr;13(4):497-510.
79. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, **Bracarda S**, Porta C, Galligioni E, Contu A. Future Oncol. 2014 Aug;10(10):1741-50.
78. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Heidenreich A, **Bracarda S**, Mason M, Ozen H, Sengelov L, Van Oort I, Papandreou C, Fossa S, Hitier S, Climent MA; European investigators. Eur J Cancer. 2014 Apr;50(6):1090-9.
77. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzi V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, **Bracarda S**. PLoS One. 2013 Dec 30;8(12):e83026.
76. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. **Bracarda S**, Sisani M, Marrocolo F, Hamzaj A, del Buono S, De Simone V. Crit Rev Oncol Hematol. 2014 Mar;89(3):386-93.
75. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. **Bracarda S**, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Carteni G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Future Oncol. 2014 May;10(6):975-83.
74. Poor survival in prostate cancer patients with primary refractoriness to docetaxel. Di Lorenzo G, **Bracarda S**, Buonerba C, Aieta M, Mirone V. Eur Urol. 2014 Feb;65(2):505-7.
73. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Procopio G, Verzoni E, **Bracarda S**, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; Italian Trials in Medical Oncology (ITMO) group. Ann Oncol. 2013 Dec;24(12):2967-71.
72. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Iacovelli R, Altavilla A, Procopio G, **Bracarda S**, Santoni M, Cascinu S, Cortesi E. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):323-7.
71. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Melichar B, **Bracarda S**, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J; BEVLiN Investigators. Ann Oncol. 2013 Sep;24(9):2396-402.

70. The treating scenario in genitourinary oncology: what is new? Part 2. **Bracarda S**, Montironi R, Porta C, Szczylic C, Bearz A, Carteni G, Bellmunt J. *Future Oncol.* 2013 Jun;9(6):803-6.
69. The treating scenario in genitourinary oncology: what is new? Part 1. **Bracarda S**, Montironi R, Porta C, Szczylic C, Bearz A, Carteni G, Bellmunt J. *Future Oncol.* 2013 Jun;9(6):797-801.
68. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, **Bracarda S**, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. *Ann Oncol.* 2013 Aug;24(8):2062-7.
67. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Procopio G, Bellmunt J, Dutcher J, **Bracarda S**, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE. *Br J Cancer.* 2013 Feb 5;108(2):311-8.
66. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, **Bracarda S**, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V. *Urology.* 2013 Jan;81(1):143-9.
65. Abiraterone in metastatic prostate cancer without previous chemotherapy. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efsthathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators (**Name in the Appendix List**). *N Engl J Med.* 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: *N Engl J Med.* 2013 Feb 7;368(6):584.
64. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. (**Name in the Appendix List**). *Eur Urol.* 2013 Dec;64(6):994-1002.
63. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). **Bracarda S**, Porta C, Boni C, Santoro A, Mucciarini C, Pazzola A, Cortesi E, Gasparro D, Labianca R, Di Costanzo F, Falcone A, Cinquini M, Caserta C, Paglino C, De Angelis V. *Eur Urol.* 2013 Feb;63(2):254-61.
62. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. Ferrero A, Sperone P, Ardito A, Rossi G, Del Buono S, Priola AM, **Bracarda S**, Taberna E, Terzolo M, Berruti A. *J Endocrinol Invest.* 2013 Mar;36(3):148-52.
61. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. **Bracarda S**, Hutson TE, Porta C, Figlin RA, Calvo E, Grünwald V, Ravaud A, Motzer R, Kim D, Anak O, Panneerselvam A, Escudier B. *Br J Cancer.* 2012 Apr 24;106(9):1475-80.
60. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, **Bracarda S**, Hutson TE, Escudier B, Grünwald V, Kim D, Panneerselvam A, Anak O, Motzer RJ. *Eur Urol.* 2012 Apr;61(4):826-33.
59. 3rd Pavia international symposium on advanced kidney cancer. Porta C, Bracarda S. *Expert Opin Pharmacother.* 2012 Feb;13(3):445-53.
58. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

- Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, **Bracarda S**, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA. Eur J Cancer. 2012 Feb;48(3):333-9.
57. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. **Bracarda S**, Ruggeri EM, Monti M, Merlano M, D'Angelo A, Ferraù F, Cortesi E, Santoro A; Sorafenib Working Group. Crit Rev Oncol Hematol. 2012 Jun;82(3):378-86.
56. Contemporary role of androgen deprivation therapy for prostate cancer. Pagliarulo V, **Bracarda S**, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE. Eur Urol. 2012 Jan;61(1):11-25.
55. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirota N, Bodrogi I; REACT Study Group. (*Name in the Appendix List*). Eur J Cancer. 2012 Feb;48(3):324-32.
54. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H. Cancer Treat Rev. 2012 Apr;38(2):127-32.
53. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Procopio G, Verzoni E, **Bracarda S**, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E. Br J Cancer. 2011 Apr 12;104(8):1256-61.
52. Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010. Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E; NIBIT, Parmiani G. Cancer Immunol Immunother. 2011 Jun;60(6):901-7.
51. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. Bracarda S, Logothetis C, Sternberg CN, Oudard S. BJU Int. 2011 Apr;107 Suppl 2:13-20.
50. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, **Bracarda S**, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B. Ann Oncol. 2011 Aug;22(8):1812-23.
49. Biologic tools to personalize treatment in genitourinary cancers. Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e42-8.
48. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, Ruggeri EM, Sperduti I, **Bracarda S**, Pinnarò P, Lanzetta G, Muti P, Cognetti F, Carlini P. BMC Cancer. 2010 Dec 9;10:675.
47. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon- α 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. **Bracarda S**, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B. BJU Int. 2011 Jan;107(2):214-9.
46. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Gore ME, Hariharan S, Porta C, **Bracarda S**, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. Cancer. 2011 Feb 1;117(3):501-9.

45. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, **Bracarda S**, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-1 Study Group. *Cancer*. 2010 Sep 15;116(18):4256-65.
44. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, **Bracarda S**, Ravaud A, Golding S, Jethwa S, Sneller V. *J Clin Oncol*. 2010 May 1;28(13):2144-50.
43. Redefining the role of interferon in the treatment of malignant diseases. **Bracarda S**, Eggermont AM, Samuelsson J. *Eur J Cancer*. 2010 Jan;46(2):284-97.
42. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Gore ME, Szczylik C, Porta C, **Bracarda S**, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. *Lancet Oncol*. 2009 Aug;10(8):757-63.
41. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group. *J Natl Cancer Inst*. 2008 Oct 15;100(20):1454-63.
40. Sequential therapies in metastatic renal cell carcinoma: option or strategy? **Bracarda S**, De Simone V. *Eur Urol*. 2008 Dec;54(6):1219-20; discussion 1221-2.
39. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, **Bracarda S**, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. *Lancet*. 2008 Aug 9;372(9637):449-56.
38. IGG practice guidelines on germ cell tumor in adult male patients. De Giorgi U, Nicolai N, Tana S, Tavolini IM, Palazzi S, **Bracarda S**, Tedeschi L, Palmieri G, Frassinetti L, Da Pozzo L, Pastorino U, Emiliani E, Marangolo M, Pizzocaro G, Rosti G, Salvioni R; Italian Germ cell cancer Group. *Tumori*. 2008 Jan-Feb;94(1):96-109.
37. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Melichar B, Koralewski P, Ravaud A, Pluzanska A, **Bracarda S**, Szczylik C, Chevreau C, Filippek M, Delva R, Sevin E, Négrier S, McKendrick J, Santoro A, Pisa P, Escudier B. *Ann Oncol*. 2008 Aug;19(8):1470-6.
36. 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells. Minelli A, Bellezza I, Tucci A, Conte C, **Bracarda S**, Culig Z. *Prostate*. 2008 Mar 1;68(4):360-72.
35. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, Ravaud A, **Bracarda S**, Szczylik C, Chevreau C, Filippek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Grusfeld A, Moore N; AVOREN Trial investigators. *Lancet*. 2007 Dec 22;370(9605):2103-11.
34. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. **Bracarda S**, Caserta C, Sordini L, Rossi M, Hamzay A, Crinò L. *Ann Oncol*. 2007 Jun;18 Suppl 6:vi22-5. Review.
33. Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Bracarda S. *Eur Urol*. 2008 Feb;53(2):331. No abstract available.
32. Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Bracarda S. *Eur Urol*. 2007 Dec;52(6):1698-9. No abstract available.

31. The medical management of prostate cancer: a multidisciplinary team approach. Sternberg CN, Krainer M, Oh WK, **Bracarda S**, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. BJU Int. 2007 Jan;99(1):22-7. Epub 2006 Sep 6. Review. No abstract available.
30. Mechanism of 2-chloroadenosine toxicity to PC3 cell line. Minelli A, Bellezza I, Agostini M, **Bracarda S**, Culig Z. Prostate. 2006 Sep 15;66(13):1425-36.
29. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Bellezza I, **Bracarda S**, Caserta C, Minelli A. Mol Genet Metab. 2006 Jun;88(2):114-22. Epub 2006 Feb 17. Review.
28. [Guidelines for prostate biopsy]. Bianchi G, **Bracarda S**, Bruzi P, Bufo P, Celesti R, De Maria M, Gallucci M, Gelmini A, Guidi G, Manente P, Rusticali B, Tombesi M, Viafora C, Zorat P; Gruppo Italiano Biopsia Prostatica. Arch Ital Urol Androl. 2005 Sep;77(3 Suppl 1):63-5. Italian. No abstract available.
27. Cancer of the prostate. **Bracarda S**, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Crit Rev Oncol Hematol. 2005 Dec;56(3):379-96. Review.
26. [The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer]. Bracarda S, Caserta C, Tonato M. Suppl Tumori. 2004 Jul-Aug;3(4):S93. Italian. No abstract available.
25. Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer. Maranzano E, Crinò L, Piro F, Meacci L, **Bracarda S**, de Angelis V, Darwish S, Minotti V, Panizza BM, de Marinis F, Latini P, Tonato M. Lung Cancer. 2002 Jul;37(1):79-85.
24. [Chemotherapy of prostate cancer: potential role of docetaxel]. Bracarda S. Tumori. 2001 Nov-Dec;87(6):A12-4. Review. Italian. No abstract available.
23. Quality of life studies and genito-urinary tumors. Bertetto O, **Bracarda S**, Tamburini M, Cortesi E. Ann Oncol. 2001;12 Suppl 3:S43-8. Review.
22. Prostate cancer: correlation between local and systemic disease. Marzi M, Rosi P, Mearini E, Bracarda S, Cesaroni S, Porena M. Minerva Urol Nefrol. 1999 Dec;51(4):187-90.
21. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. **Bracarda S**, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M. Cancer. 2000 Mar 15;88(6):1438-44.
20. [Carcinoma of the prostate: correlation between local staging and systemic progression]. Rosi P, Marzi M, Mearini E, **Bracarda S**, Valli PP, Petroni PA, Porena M. Arch Ital Urol Androl. 1996 Dec;68(5 Suppl):91-5. Italian.
19. [Echographic follow-up after radical prostatectomy]. Rosi P, Valli PP, Petroni PA, Morcellini R, **Bracarda S**, Porena M. Arch Ital Urol Androl. 1996 Dec;68(5 Suppl):43-8. Review. Italian.
18. Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. Mearini E, **Bracarda S**, Crinò L, Zucchi A, Porena M. Eur Urol. 1996;29(1):119-21. Review.
17. [Echographic features of testicular neoplasms. Our experience]. Rosi P, Valli PP, Marzi M, Cesaroni S, **Bracarda S**, Porena M. Arch Ital Urol Androl. 1994 Sep;66(4 Suppl):183-5. Italian.
16. [Cystic renal pathology]. Rosi P, Cesaroni M, **Bracarda S**, Rociola W, Virgili G. Arch Ital Urol Androl. 1993 Aug;65(4):341-50. Italian.

15. Reliability and validity of a quality of life questionnaire in cancer patients. Ballatori E, Roila F, Basurto C, Bracarda S, Picciafuoco M, Soldani M, Crinò L, Tonato M, Milella G, Del Favero A. Eur J Cancer. 1993;29A Suppl 1:S63-9.
14. Ondansetron. Roila F, Tonato M, Basurto C, Bracarda S, Sassi M, Lupattelli M, Picciafuoco M, Ballatori E, Del Favero A. Eur J Cancer. 1993;29A Suppl 1:S16-21. Review.
13. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, **Bracarda S**, Rosso R, et al. Eur J Cancer. 1993;29A(5):687-92.
12. The role of chemotherapy in the treatment of prostatic carcinoma. Tonato M, **Bracarda S**. Rays. 1993 Jan-Mar;18(1):87-93. Review. English, Italian. No abstract available.
11. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. Roila F, **Bracarda S**, Basurto C, Sassi M, Lupattelli M, Picciafuoco M, Boschetti E, Del Favero A, Tonato M. Am J Clin Oncol. 1992 Apr;15(2):112-4.
10. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Roila F, Boschetti E, Tonato M, Basurto C, **Bracarda S**, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E, et al. Am J Clin Oncol. 1991 Jun;14(3):238-42.
9. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Roila F, Lupattelli M, Sassi M, Basurto C, **Bracarda S**, Picciafuoco M, Boschetti E, Milella G, Ballatori E, Tonato M, et al. Ann Oncol. 1991 Jun;2(6):437-9.
8. Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. Roila F, Basurto C, **Bracarda S**, Sassi M, Lupattelli M, Picciafuoco M, Boschetti E, Tonato M, Del Favero A. Eur J Cancer. 1991;27(2):119-21.
7. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Roila F, **Bracarda S**, Tonato M, Marangolo M, Bella M, Donati D, Cetto G, Del Favero A. Clin Oncol (R Coll Radiol). 1990 Sep;2(5):268-72.
6. Inflammatory reaction presages response in melanoma skin lesions during i.m. rIFN alpha-2a-based treatment. **Bracarda S**, Roila F, Basurto C, Tonato M. Ann Oncol. 1990 Sep;1(5):381. No abstract available.
5. A pilot study of metoclopramide, dexamethasone, diphenhydramine and acupuncture in women treated with cisplatin. Aglietti L, Roila F, Tonato M, Basurto C, **Bracarda S**, Picciafuoco M, Ballatori E, Del Favero A. Cancer Chemother Pharmacol. 1990;26(3):239-40.
4. A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients. Roila F, Basurto C, **Bracarda S**, Picciafuoco M, Ballatori E, Del Favero A, Tonato M. Oncology. 1990;47(5):415-7.
3. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. Roila F, Tonato M, Basurto C, Picciafuoco M, **Bracarda S**, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L, et al. J Clin Oncol. 1989 Nov;7(11):1693-700.
2. Antiemetic therapy in patients treated with cisplatin chemotherapy. Roila F, Basurto C, **Bracarda S**, Del Favero A, Tonato M. J Chemother. 1989 Jul;1(4 Suppl):1281-5. Review. No abstract available.

1. A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antineoplastic agents. Basurto C, Roila F, **Bracarda S**, Tonato M, Ballatori E, Del Favero A. Am J Clin Oncol. 1988 Oct;11(5):594-6.

Terni, Terni, May 30, 2022

A handwritten signature in black ink, appearing to read 'Sergio Bracarda', is written on a light-colored, textured background.